

Appendix 4D

Omni Bridgeway Limited ("OBL", "the Company" or "the Parent")
ABN 45 067 298 088

Half year ended 31 December 2023

Results for announcement to the market

Current reporting period: Half year ended 31 December 2023

Previous reporting period: Half year ended 31 December 2022

	Up/Down	Percentage Change	\$'000
Revenue from ordinary activities	Up	42%	15,629
Loss from ordinary activities after tax attributable to members	Down	(11)%	(47,627)
Net loss for the period attributable to members	Down	(11)%	(47,627)
Other comprehensive loss after tax for the period	Down	(239)%	(10,806)
Total comprehensive income after tax for the period	Up	201%	22,551

Dividends

The Directors have determined not to pay a dividend for the period ended 31 December 2023 to equity holders of the parent company. The Directors did not pay a final dividend for the financial year ended 30 June 2023.

The Directors have determined they will consider, and where appropriate, implement, a regular semi-annual dividend which reflects the cash position and performance of the Company at the time of the dividend and the likely demand for cash over the ensuing 12 month period. The Company has put in place a dividend reinvestment plan and, on appropriate occasions, will arrange underwriting to reduce the impact a particular dividend might otherwise have on cash.

Net tangible assets per ordinary share

	31-Dec-23	30-Jun-23
['] P	\$	\$
Basic net tangible assets per ordinary share ¹	0.98	0.68
Basic net assets per ordinary share	2.91	2.89
Book value of investments per ordinary share	1.78	1.99

1) Net tangible assets excludes intangible assets - litigation contracts in progress, goodwill, claims portfolio and contract assets.

		Percentage Lost
	Country of	At
	Establishment	31-Dec-23
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20

Entities over which control was gained or lost during the period The Company has lost control over the following existing entities during the period.		
		Percentage Lost
	Country of Establishment	At 31-Dec-23
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20
The Company has established the following entities during the period.		
	Per	rcentage Owned
	Country of Establishment	At 31-Dec-23
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20
Omni Bridgeway (Fund 4) S2 L.P.	USA	20
	USA	81
Omni Bridgeway (Fund 8) Delaware SPV LLC		
Omni Bridgeway (Fund 8) Delaware SPV LLC Omni Bridgeway (Fund 8) Guernsey SPV Limited	Guernsey	81
	Guernsey USA	81 81
Omni Bridgeway (Fund 8) Guernsey SPV Limited	*	

Associates

The Company has the following associates during the period:

		Percentage Owned
	Country of	At
1	Incorporation	31-Dec-23
OB Capital Cooperatief UA	Netherlands	5
Omni Bridgeway (Fund 1) LLC	USA	100
Omni Bridgeway (Fund 4) Eagle SPV LLC	USA	20

Foreign operations

n compiling this report International Financial Reporting Standards have been used as the basis of preparation for all foreign operations.

Explanation of results

术he attached Interim Financial Report for the half year ended 31 December 2023 forms part of this document. This Interim Financial Report is to be read in conjunction with the most recent annual financial report. A copy of the 2023 annual financial report and other documents are available on the website at www.omnibridgeway.com or on the ASX website at www.asx.com.au.

Review opinion

 π he review opinion of the Company's auditors, BDO, is attached to the financial statements.

Guillaume Leger

Global Chief Financial Officer Date: 28 February 2024





Half year ended 31 December 2023

Omni Bridgeway Limited

ABN 45 067 298 088

Interim Financial Report

for the half year ended 31 December 2023

Contents	
Contents	
Directors' Report	
Notes to the Directors' Report	
Auditor's Independence Declaration	10
Interim Consolidated Statement of Comprehensive Income	1
Interim Consolidated Statement of Financial Position	1:
Interim Consolidated Statement of Cash Flows	1:
Interim Consolidated Statement of Changes in Equity	10
Notes to the Interim Consolidated Financial Statements	1.
Directors' Declaration Independent Review Report	3 ¹ 4 ¹
Corporate Information	4.
Glossary	4:
G. G	

for the half year ended 31 December 2023

Directors' Report

The Directors present their report (referred to hereafter as the "Interim Financial Report"), together with the financial statements, on the consolidated entity (referred to hereafter as the "consolidated entity" or "the Group") consisting of Omni Bridgeway Limited (referred to hereafter as "OBL", "the Company" or "the Parent") and the entities it controlled at the end of, or during, the half year ended 31 December 2023.

Directors

The names of the Company's Directors in office during the half year ended 31 December 2023 and until the date of this report are as below. Unless stated otherwise, the Directors were in office for this entire period.

Michael Kay

Non-Executive Chairman

Andrew Saker

Managing Director & CEO (retired 26 October 2023)

Raymond van Hulst

Managing Director & CEO (appointed 26 October 2023), former Executive Director and Co-Chief Investment Officer – EMEA

Michael Green Karen Phin Non-Executive Director
Non-Executive Director

Christine Feldmanis

Non-Executive Director

Review and results of operations

Highlights for the half year ended 31 December 2023

Operational highlights¹

US\$485 million² first close of Fund 4 and Fund 5 series II capital raise on improved cost coverage terms.

€135 million first tranche of debt capital raised for our €300 million Fund 8, focused on global enforcement investments.

Significant expansion of our capabilities in the UK, the world's second largest litigation finance market.

Investment income of \$235.7 million, including income yet to be recognised, with \$50.1 million provisionally attributable to OBL.

12 full completions, 6 partial completions, and a secondary market transaction achieving an overall MOIC of 2.4x, and an IRR of 55%.

US\$21.5 million cash proceeds from the sale of a 25% interest in a portfolio of 15 intellectual property (IP) investments in Fund 4.

\$260 million of new investment commitments with 38% improved pricing on FY23.

\$182 million strong pipeline of new investment opportunities representing a further 29% of our commitments target for the year ending 30 June 2024.

Possible investment completions with an estimated portfolio value (EPV) of \$5.1 billion over the next 12 months (rolling period).

Total cash and receivables of \$291.2 million; OBL only cash and receivables of \$122.4 million (\$80.9 million in OBL balance sheet cash and \$40.1 million of OBL share of cash and receivables within Funds), plus \$60 million in undrawn debt.

Financial highlights³

Total income of \$135.8 million (including a net gain on deconsolidation of the Fund 4 IP portfolio) derived from diversified sources comprising litigation completions, a secondary market sale, management fees, and interest revenue.

Group profit after tax (before non-controlling interests (**NCI**)) of \$33.4 million (1H23: \$30.1 million loss after tax); with \$47.6 million loss attributable to OBL (the Group's equity holders) and \$81.0 million profit attributable to NCI.

Employee expenses of \$34.4 million decreased 12% due to team optimisation, a reduction in contractors and higher capitalised costs of investment managers.

Corporate overheads of \$9.0 million increased 4% due mainly to the amortisation of the Fund 8 insurance premium, notwithstanding significant reductions in other corporate overhead expenses.

Carrying value of litigation investments of \$654.7 million (30 June 2023: \$596.7 million) across 285 funded litigation investments. Negative case developments including lower than anticipated income, extended duration and adverse milestones associated with a funded law firm portfolio have resulted in a \$44.9 million reduction of the carrying value.

Represents non-IFRS information. Here Fund 5 is presented at 100% for consistency of presentation across OBL's Funds.

² Inclusive of OBL's co-funding (OBL's commitment of US\$100 million to each Series II fund is capped at 20% of the ultimate fund size (i.e. after further closings).

³ Per the Group Consolidated Financial Statements.

for the half year ended 31 December 2023

Directors' Report (continued)

Review and results of operations (continued)

Commitments⁴


The Group's geographic and asset diversification assists in mitigating the risk of any increased competition or regulatory intervention arising in any one region. New commitments are the investment into future income streams and enable the Group to achieve economies of scale to diversify risk and provide superior risk adjusted returns in this asset class.

The stated target for the year ending 30 June 2024 includes \$625 million in new commitments or equivalent value, prioritising value over volume to reflect potential for improved pricing on new commitments.

New commitments of \$259.8 million were made in period ending 31 December 2023 with approximately 38% higher pricing compared to FY23, based on the NPV of loss-adjusted probability-weighted investment cashflows per dollar of new commitments for the total portfolio.

This accounts for 42% of the full year commitment goal and compares to an average 47% of commitment target reached as at 31 December over the last three years. On an equivalent value basis, due to improved pricing, this accounts for 58% of the full year value generation goal.

An additional 29 exclusive term sheets have been agreed, representing approximately \$182 million in investment opportunities, which if converted into funded investments is a further 29% of our commitment target for the year ending 30 June 2024.



Portfolio review²

December 2023, in conjunction with the development of probabilistic models for the transition to fair value, we undertook a thorough review of methodology and key assumptions underpinning quantum and duration estimates for all investments. This also allowed us to review the historic possible completion period (**PCP**) and estimated portfolio value (**EPV**) slippage by benchmarking the probabilistic model assumptions against the EPV and PCP.

Although neither method is necessarily more accurate on a case-by-case basis given the inherent uncertainties of litigation, we have revised EPV and PCP estimates for the portfolio. Completions are inherently uncertain and beyond our control, and investments may still complete as per prior EPV and PCP estimates.

While the revisions led to a combination of positive and negative EPV adjustments, the overall impact was a reduction in EPV of \$1.3 billion at 31 December 2023 compared to 30 September 2023.

The EPV (including conditionally funded and investment committee (IC) approved investments) at 31 December 2023 is \$27.6 billion, down 10% compared to 30 September 2023. Excluding the secondary market disposal, EPV was 8% lower compared to 30 September 2023.

⁴ Represents non-IFRS information. Here Fund 5 is presented at 100% for consistency of presentation across OBL's Funds.

for the half year ended 31 December 2023

Directors' Report (continued)

Review and results of operations (continued)

In line with the indicated changed disclosures on EPV, included in our 2Q24 Investment Portfolio Report dated 25 January 2023, we no longer report EPV with PCP for specific financial years.

This is replaced by an EPV of \$5.1 billion which is assessed to possibly complete in the 12 months following the end of the quarter. This 12-month rolling EPV is based on investments which are subject to various stages of (anticipated) settlement discussions or for which an award or a judgment is expected. All or only part of these may actually complete during the 12 month period. This approach better reflects the timing risk associated with investment completions, which are determined by the courts as well as the litigation and resolution approach of claimants and defendants, neither of which we control or can accurately predict. This also aligns with our legal finance peers, none of whom provide such information in their disclosures.

At 31 December 2023, there were 314 investments (30 June 2023: 301) in the Group's total portfolio, including 29 conditionally funded and IC approved investments.

EPV profile^{5,6}

\$ million	#	Average duration	Possible EPV completion in the next 12 months	Total EPV
Balance sheet	5	8.8 yrs	5	106
Funds 2&3	21	4.6 yrs	1,533	3,097
Fund 4 ⁷	45	1.6 yrs	1,183	7,588
Fund 5	70	1.7 yrs	1,631	9,976
Fund 6	141	7.9 yrs	736	3,600
Fund 8 ⁸	3	0.6 yrs	-	81
Total funded investments	285	5.1 yrs	5,088	24,448
Conditionally funded investments	10			1,394
IC approved investments	19			1,787
Total all investments	314			27,629

Secondary market

The Group continues to utilise secondary market sales as a risk management strategy to reduce duration and completion risks, while enhancing liquidity and internal rates of return. In December 2023, we completed the sale of a 25% interest in a portfolio of 15 intellectual property (IP) investments (Investments) in Fund 4 for initial cash proceeds of US\$21.5 million, representing a multiple on invested capital (MOIC) of 2.0x of the apportioned aggregated deployments to date. The purchaser will receive a preferred return on its deployments alongside OBL, beyond which OBL retains further profit rights on the 25% interest.

Upon completion of the sale, each of the investments were treated as partial completions in our fund and performance reporting, the Fund 4 IP portfolio was deconsolidated and resulted in a net gain before non-controlling interests (**NCI**) of approximately US\$51.0 million EBITDA (after NCI of approximately US\$4.6 million EBITDA) before management and performance fees. The EPV relating to the 75% retained interest of the Investments is reflected in the Fund 4 EPV profile. The residual interest in the Investments is recognised as "Litigation Investments - investment in associates" within the Group Consolidated Financial Statements.

Fund capital raising

The US\$485 million first close of the Fund 4 and Fund 5 series II capital raising (**Series II**) completed in December 2023 on improved cost coverage terms. The continued and additional investment by existing investors together with OBL's co-funding provides a strong base to market the remaining US\$515 million capacity of Series II.

Series II has been structured to improve the cost coverage by OBL as manager through the inclusion of transaction fees payable on investments. Transaction fees, comparable to facility fees in traditional lending, are targeted to average around 2.5% to 3.0% of investment commitments and will typically be payable to OBL in the first years of an investment's life cycle. The transaction fees represent a significant improvement on the fee terms of the first series, in line with our stated objective to increase cost coverage contribution from future funds.

⁵ Represents non-IFRS information. Here Fund 5 is presented at 100% for consistency of presentation across OBL's Funds.

⁶ Further information on terms, including definitions of key concepts, used in the table above is detailed at the end of the Directors' Report and available in our Glossary at https://omnibridgeway.com/investors/notes-to-quarterly-reports and should be read in conjunction with this report.

⁷ The IP portfolio in Fund 4 was deconsolidated on 8 December 2023 following the sale of a 25% interest in these investments. The EPV relating to the 75% retained interest of the IP portfolio is included. The residual interest of the IP portfolio in Fund 4 is recognised as an investment in associate in the Group Consolidated Financial Statements.

⁸ Including investments transferred from the warehouse and investments currently anticipated being transferred.

for the half year ended 31 December 2023

Directors' Report (continued)

Review and results of operations (continued)

In September 2023, the first €135 million tranche of debt was raised for our €300 million Fund 8, focused on global enforcement investments. Capital loss in Fund 8 is insured pursuant to a principal protection insurance indemnity of an initial amount of €135 million. The insurance policy has an option to extend the indemnity to €270 million, which provides for a second series or an upsize of series one. Omni Bridgeway has committed an initial €15 million standby equity and can increase to €30 million when the insurance uplift option is exercised. The Fund 8 insurance premium and establishment costs, previously paid by OBL on behalf of the fund were received as a \$10.3 million cash reimbursement to OBL during the period ending 31 December 2023.

Board and management

On 26 October 2023, Raymond van Hulst was appointed Managing Director and Chief Executive Officer (CEO) of the Group following the retirement of Andrew Saker, after more than eight years in the role.

Mr van Hulst, former Executive Director and Co-Chief Investment Officer of EMEA, previously held a wide range of senior roles in the Company having been a key member of the legacy Omni Bridgeway team for over 20 years, and brings a breadth of experience in legal firms. Since the merger of IMF Bentham and Omni Bridgeway Holding B.V in 2019, Mr van Hulst has focused on the globalisation of the enforcement investment strategy and integration of the businesses. His experience provides business continuity and a smooth transition.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the half year ended 31 December 2023.

Dividends

The Directors have determined not to pay a dividend for the period ended 31 December 2023 to equity holders of the parent company. The Directors did not pay a final dividend for the financial year ended 30 June 2023.

Rounding

The amounts contained within this report have been rounded to the nearest \$1,000 or \$100,000 (where rounding is applicable) under the option available to the Company under ASIC Corporations (Rounding in Financial/Director's Reports) Instrument 2022/519.

Subsequent events after reporting date

In January 2024, we received a positive appeal decision relating to a Fund 4 investment, and in February 2024, we reached settlement in two Fund binvestments for which we anticipate recognising, in aggregate, approximately \$29 million of income in by 30 June 2024.

Except as disclosed in this report there have been no other subsequent events after the reporting date that are not included in the Group Consolidated Financial Statements.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Signed in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

Michael Kay

A. T. Kay.

Non-Executive Chairman Date: 28/02/24

for the half year ended 31 December 2023

Notes to the Directors' Report

Further information

Certain terms used throughout the Directors' Report including, but not limited to, investment income, fee revenue, estimated portfolio value (EPV), commitments and fair value (FV) are presented as non-IFRS information.

Commitments, EPV and FV include conditional and Investment Committee approved investments. The investments of Funds 2&3, Fund 4, Fund 6 and Fund 8 are consolidated within the Group Consolidated Financial Statements, along with the interest of the respective external Fund investors if applicable.

Fund 1 was deconsolidated on 31 May 2023. The associated EPV, effective from that date, is excluded from this document.

The Fund 4 IP portfolio was deconsolidated on 8 December 2023 following the sale of a 25% interest in these investments. The EPV relating to the 75% retained interest is proportionally reflected in the Fund 4 EPV profile.

Fund 1 and Fund 5 are not consolidated within the Group Consolidated Financial Statements; the residual interest in Fund 1 and in the Fund 4 IP portfolio is recognised as an investment in associate, whereas Fund 5 is brought in at the Group's attributable 20% share of income, assets, and liabilities.

Throughout the Directors' Report, Fund 5 is presented at 100% values (except where otherwise stated) for consistency of presentation across OBL's funds.

Where investments are co-funded with an entity which is not affiliated with Omni Bridgeway, the co-funded proportion of the applicable investment is excluded from the Directors' Report (except where otherwise stated).

Further information on the terms, including definitions of key concepts, is available in our Glossary at https://omnibridgeway.com/investors/omnibridgeway.com/investors/notes-to-quarterly-reports and should be read in conjunction with this report.



Tel: +61 8 6382 4600 Fax: +61 8 6382 4601 www.bdo.com.au Level 9 Mia Yellagonga Tower 2 5 Spring Street Perth, WA 6000 PO Box 700 West Perth WA 6872 Australia

DECLARATION OF INDEPENDENCE BY GLYN O'BRIEN TO THE DIRECTORS OF OMNI BRIDGEWAY LIMITED

As lead auditor for the review of Omni Bridgeway Limited for the half-year ended 31 December 2023, I declare that, to the best of my knowledge and belief, there have been:

- 1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- 2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Omni Bridgeway Limited and the entities it controlled during the period.

Glyn O'Brien

Director

BDO Audit (WA) Pty Ltd

Perth

28 February 2024

Interim Consolidated Statement of Comprehensive Income

for the half year ended 31 December 2023

		Consolidate	:d	
	Notes	31-Dec-23	31-Dec-22	
		\$'000	\$'000	
Continuing operations				
Revenue from contracts with customers	2	12,229	5,997	
Interest revenue	3	3,400	5,027	
Net gain on derecognition of litigation investments - intangible assets	4	45,613	1,195	
Net loss on disposal of litigation investments - purchased claims	10	(82)	-	
Net gain on deconsolidation of subsidiaries	12	73,149	6,376	
Other income		1,528	971	
Total income		135,837	19,566	
Finance costs	5(a)	462	2,636	
Amortisation of litigation investments - claims portfolio	5(b)	4,045	2,727	
Depreciation expense	5(c)	2,200	1,950	
Employee benefits expense	5(d)	34,359	39,033	
Corporate and office expense	5(e)	9,007	8,635	
Other expenses	5(f)	8,614	5,575	
mpairment expense and adverse costs - litigation investments	5(g)	38,444	3,725	
Share of net loss/(profit) in associates	12	8,213	(1,337	
Profit/(Loss) before tax and fair value adjustments	-	30,493	(43,378	
Fair value adjustments on financial liabilities		982	(21	
Profit/(Loss) before tax	_	31,475	(43,399	
Income tax benefit	6	(1,882)	(13,263	
Profit/(Loss) for the period		33,357	(30,136	
1 10110 (2033) 101 the period	_	33,337	(30,130	
Attributable to:				
Equity holders of the Parent	7	(47,627)	(42,793	
Non-controlling interests		80,984	12,657	
		33,357	(30,136	
Other comprehensive income/(loss)			<u> </u>	
Items that may be subsequently reclassified to profit and loss:				
Movement in foreign currency translation reserve		(5,034)	9,574	
Items that will not be subsequently reclassified to profit and loss:				
Movement in foreign currency translation reserve attributed to				
non-controlling interests		(5,772)	(1,806	
Other comprehensive (loss)/income for the period, net of tax		(10,806)	7,768	
Total comprehensive income/(loss) for the period		22,551	(22,368	
Attributable to:				
Equity holders of the Parent		(52,661)	(33,219	
Non-controlling interests		75,212	10,851	
Loss per share attributed to the ordinary equity holders of the Company (cen	ts per share)			
Basic loss per share (cents per share)	7	(17.02)	(15.76	
Diluted loss per share (cents per share)	7	(17.02)	(15.76	

The above Interim Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying notes.

Interim Consolidated Statement of Financial Position

as at 31 December 2023

		Consolidat		
	Notes	31-Dec-23 \$'000	30-Jun-2 \$'00	
ASSETS				
Current assets				
Cash and cash equivalents	14	132,846	117,01	
Trade and other receivables	17	103,989	140,77	
Contract costs		939	93	
Other assets	18	10,118	8,00	
Income tax receivable		1,213		
Total current assets		249,105	266,72	
Non-current assets				
Trade and other receivables	17	43,049	45,66	
Litigation investments - claims portfolio	9	131,300	125,7	
Litigation investments - purchased claims	10	47,444	37,4	
Litigation investments - intangible assets	11	305,154	370,0	
Litigation investments - financial assets		13,895	7,0	
Litigation investments - investment in associates	12	156,948	56,33	
Goodwill	12	102,062	103,30	
Right of use assets and other plant and equipment		17,916	18,4	
Investment in associates	12			
/·····	12	7,433	6,98	
Contract costs	4.0	1,174	1,64	
Other assets	18	14,426	17,7	
Deferred tax assets	6	87,795	77,5	
Total non-current assets	-	928,596	868,1	
Total assets	_	1,177,701	1,134,83	
Liabilities				
Current liabilities				
Trade and other payables		48,041	50,11	
income tax payable		-	8,00	
Provisions	20	31,327	31,23	
Lease liabilities		3,570	2,93	
Litigation investment - deferred consideration		7,172	3,3	
Other financial liabilities	19	10,444	8,09	
Total current liabilities		100,554	103,7	
Non-current liabilities				
Provisions	20	1,137	1,29	
Lease liabilities		14,281	15,00	
Borrowings	15	192,065	181,63	
Litigation investment - deferred consideration		1,039	4,3	
Deferred income tax liabilities		43,938	30,8	
Other financial liabilities	19	2,053	10,7	
Other liabilities	13	8,050	2,9:	
Total non-current liabilities		262,563	246,82	
Total liabilities		363,117	350,54	
Net assets		814,584	784,28	
		014,504	701,20	
Equity	16	460.050	4.40.0	
Contributed equity	16	462,253	449,8	
Reserves Accumulated losses		(2,274) (167,118)	18,4 (119,4)	
Equity attributable to equity holders of the parent Non-controlling interests	23	292,861 521,723	348,85 435.43	
izon-controllil Ritterezrz		521,723	435,43	
		814,584	784,28	

The above Interim Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

Interim Consolidated Statement of Cash Flows

for the half year ended 31 December 2023

		Consolidate	
	Notes	31-Dec-23 \$'000	31-Dec-22 \$'000
		+ 000	4 000
Cash flows from operating activities			
Proceeds from litigation investments - claims portfolio		2,886	3,435
Payments for litigation investments - claims portfolio		(10,978)	(6,858
Proceeds from management and performance fees		8,656	6,626
Payments to suppliers and employees		(43,191)	(63,150
Interest income		1,201	721
Interest paid		(10,963)	(5,436
Income tax paid		(8,958)	(2,318
Net cash flows used in operating activities		(61,347)	(66,980
Cash flows from investing activities			
Proceeds from litigation investments - purchased claims		1,034	-
Payments for litigation investments - purchased claims		(12,432)	-
Proceeds from litigation investments - intangible assets		139,026	104,211
Payments for litigation investments - intangible assets		(87,004)	(83,360
Payments for litigation investments - capitalised overhead and employee costs		(4,867)	(3,528
Payments for plant and equipment		(28)	(521
Loans from/(to) related parties		249	(943
Proceeds from sale of interest in litigation investments	23	31,708	-
Net cash flows from investing activities		67,686	15,859
Cash flows from financing activities			
Payments of costs for issuing debt		_	(9,037
Repayment of bonds and notes		_	(149,440
Drawdown of debt facility	15	_	150,000
Drawdown of debt - Fund 8	15	10,071	_
Payments of lease liabilities		(2,384)	(2,131
Contributions from non-controlling interests	23	62,022	58,447
Distributions to non-controlling interests	23	(58,782)	(42,982
Net cash flows from financing activities		10,927	4,857
Net increase/(decrease) in cash and cash equivalents held		17,266	(46,264
Net foreign exchange difference		(1,436)	34
Cash and cash equivalents at beginning of period		117,016	158,966
Cash and cash equivalents at end of period	14	132,846	112,736

The above Interim Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

Interim Consolidated Statement of Changes in Equity

for the half year ended 31 December 2023

	Issued capital	Share based payments reserve	Foreign currency translation reserve	Option premium reserve	Convertible note reserve	Fund equity reserve	Retained earnings/ (accumulated losses)	Total	Non- controlling interest	Total equity
Consolidated	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
As at 1 July 2023	449,854	22,742	(5,913)	3,404	3,832	(5,577)	(119,491)	348,851	435,435	784,286
Profit/(Loss) for the period	_	_	_	-	_	_	(47,627)	(47,627)	80,984	33,357
Other comprehensive loss	-	_	(5,034)	-	-	_	-	(5,034)	(5,772)	(10,806)
Total comprehensive income/(loss) for the period	-	-	(5,034)	-	-	-	(47,627)	(52,661)	75,212	22,551
Equity transactions:										
Shares issued	12,399	(12,430)	-	-	-	_	-	(31)	-	(31)
Share based payments, net of tax	-	4,236	-	-	-	-	-	4,236	-	4,236
Shares issued to settle deferred and variable deferred consideration	-	-	-	_	_	_	-	_	-	_
Contributions from non-controlling interests	-	-	-	-	-	-	-	-	62,022	62,022
Distributions to non-controlling interests	-	-	-	-	-	-	-	-	(58,782)	(58,782)
Share Buy-back Scheme	-	-	-	-	-	-	-	-	-	-
Deconsolidation of Subsidiary	-	-	-	-	-	-	-	-	-	-
Changes in the proportion of equity held by non- controlling interests	_	_	(5,772)	-	_	(1,762)	_	(7,534)	7,836	302
As at 31 December 2023	462,253	14,548	(16,719)	3,404	3,832	(7,339)	(167,118)	292,861	521,723	814,584
	Issued capital	Share based payments reserve	Foreign currency translation	Option premium reserve	Convertible note reserve	Fund equity reserve	Retained earnings/ (accumulated	Total	Non- controlling interest	Total equity
			reserve				losses)			
Consolidated	\$'000	\$'000	reserve \$'000	\$'000	\$'000	\$'000	losses) \$'000	\$'000	\$'000	\$'000
Consolidated As at 1 July 2022	\$'000 406,963	\$'000 32,273		\$'000 3,404	\$'000 3,832	\$'000 (9,944)	•	\$'000 328,890		\$'000 739,499
			\$'000				\$'000		\$'000	
As at 1 July 2022		32,273	\$'000		3,832	(9,944)	\$'000 (87,832)	328,890	\$'000 410,609	739,499
As at 1 July 2022 Profit/(Loss) for the period	406,963	32,273	\$'000 (19,806)	3,404	3,832	(9,944)	\$'000 (87,832) (42,793)	328,890 (42,793)	\$'000 410,609 12,657	739,499 (30,136)
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss)	406,963	32,273 - -	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793)	328,890 (42,793) 9,574	\$'000 410,609 12,657 (1,806)	739,499 (30,136) 7,768
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period	406,963	32,273 - -	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793)	328,890 (42,793) 9,574	\$'000 410,609 12,657 (1,806)	739,499 (30,136) 7,768
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions:	406,963 - - -	32,273 - - -	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219)	\$'000 410,609 12,657 (1,806)	739,499 (30,136) 7,768 (22,368)
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions: Shares issued	406,963 - - -	32,273 - - - - (19,399)	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219)	\$'000 410,609 12,657 (1,806)	739,499 (30,136) 7,768 (22,368) (5,653)
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions: Shares issued Share based payments, net of tax Shares issued to settle deferred and variable deferred	406,963 - - - - 13,746 -	32,273 - - - - (19,399)	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219) (5,653) 5,997	\$'000 410,609 12,657 (1,806)	739,499 (30,136) 7,768 (22,368) (5,653) 5,997 30,712 58,447
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions: Shares issued Share based payments, net of tax Shares issued to settle deferred and variable deferred consideration Contributions from non-controlling interests Distributions to non-controlling interests	406,963 - - - - 13,746 -	32,273 - - - - (19,399)	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219) (5,653) 5,997	\$'000 410,609 12,657 (1,806) 10,851	739,499 (30,136) 7,768 (22,368) (5,653) 5,997 30,712 58,447 (70,976)
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions: Shares issued Share based payments, net of tax Shares issued to settle deferred and variable deferred consideration Contributions from non-controlling interests Distributions to non-controlling interests Share Buy-back Scheme	406,963 - - - - 13,746 -	32,273 - - - - (19,399)	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219) (5,653) 5,997 30,712	\$'000 410,609 12,657 (1,806) 10,851 - - - 58,447 (70,976)	739,499 (30,136) 7,768 (22,368) (5,653) 5,997 30,712 58,447 (70,976) (286)
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions: Shares issued Share based payments, net of tax Shares issued to settle deferred and variable deferred consideration Contributions from non-controlling interests Distributions to non-controlling interests Share Buy-back Scheme Deconsolidation of Subsidiary	406,963 - - - 13,746 - 30,712	32,273 - - - - (19,399)	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944) - - - - - - - - -	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219) (5,653) 5,997 30,712 - - (286)	\$'000 410,609 12,657 (1,806) 10,851 - - - 58,447 (70,976) - (57,690)	739,499 (30,136) 7,768 (22,368) (5,653) 5,997 30,712 58,447 (70,976)
As at 1 July 2022 Profit/(Loss) for the period Other comprehensive income/(loss) Total comprehensive income/(loss) for the period Equity transactions: Shares issued Share based payments, net of tax Shares issued to settle deferred and variable deferred consideration Contributions from non-controlling interests Distributions to non-controlling interests Share Buy-back Scheme	406,963 - - - 13,746 - 30,712	32,273 - - - - (19,399)	\$'000 (19,806) - 9,574	3,404 - -	3,832 - -	(9,944)	\$'000 (87,832) (42,793) - (42,793)	328,890 (42,793) 9,574 (33,219) (5,653) 5,997 30,712	\$'000 410,609 12,657 (1,806) 10,851 - - - 58,447 (70,976)	739,499 (30,136) 7,768 (22,368) (5,653) 5,997 30,712 58,447 (70,976) (286)

The above Interim Statement of Changes in Equity should be read in conjunction with the accompanying notes.

for the half year ended 31 December 2023

About this report

The interim consolidated financial statements of Omni Bridgeway Limited ("OBL", "the Company" or "the Parent") and its subsidiaries ("the Group" or "consolidated entity") for the half-year ended 31 December 2023 was authorised for issue in accordance with a resolution of the Directors on 28 February 2024. The principal activities of the entities within the consolidated group are:

- (i) the investment into and management of Funds (or Fund-like structures) that are focused on investing into litigation and dispute resolution matters globally; and
- (ii) the continued holding of direct investments into similar litigation and dispute resolution matters.

Omni Bridgeway Limited (ABN 45 067 298 088) is a for profit company incorporated and domiciled in Australia and limited by shares that are publicly traded on the Australian Securities Exchange (ASX code: OBL).

a. Basis of preparation

This interim consolidated financial report for the half-year ended 31 December 2023 is a condensed general purpose financial report prepared in accordance with AASB 134 and IAS 34 Interim Financial Reporting. The Group has prepared the financial statements on the basis that it will continue to operate as a going concern. The Directors consider that there are no material uncertainties that may cast significant doubt over this assumption. They have formed a judgment that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and not less than 12 months from the end of the reporting period.

This interim consolidated financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the Group as the annual financial report.

It is recommended that the interim consolidated financial report for the half year be read in conjunction with the annual report for the year ended 30 June 2023 and considered together with any public announcements made by the Company during the half-year ended 31 December 2023 in accordance with the continuous disclosure obligations of the Corporations Act 2001 and the ASX Listing Rules.

The amounts contained within this report have been rounded to the nearest \$1,000 or \$100,000 (where rounding is applicable) under the option available to the Company under ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/91.

Basis of consolidation

The interim consolidated financial statements comprise the financial statements of Omni Bridgeway Limited and its subsidiaries, as listed in Note 23, at 31 December 2023.

c. Presentation currency

For the purpose of the interim consolidated financial statements, the results and the financial position of each entity are expressed in Australian dollars, which is the functional and presentation currency for the Company.

d. Significant accounting policies

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2023. All new and amended accounting standards and interpretations effective from 1 July 2023 were adopted by the Group with no material impact.

e. New or amended Accounting Standards and Interpretations adopted

Australian accounting standards and interpretations that have recently been issued or amended but are not yet effective have not been adopted by the consolidated entity for the half-year ended 31 December 2023. The Group will assess the impact of these new standards during the reporting period to which they are applicable.

f.___ Significant accounting judgments, estimates and assumptions

The significant accounting judgments, estimates and assumptions that have been applied in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 30 June 2023.

for the half year ended 31 December 2023 (continued)

A. RESULTS FOR THE HALF-YEAR

Note 1: Segment Information

The Group only operates in one industry, being funding and provision of services in relation to dispute resolution. For management purposes, the Group is organised into operating segments comprising the OBL Group's corporate operations and the Group's fund structures.

The OBL Group's wholly owned subsidiaries own historical litigation in progress investments and provide investment management advisory and administration services to the Group's fund structures in the following locations:

- Australia
 - United States
 - Canada
 - Asia
 - New Zealand
- Latin America
- Europe, Middle East and Africa (EMEA)

The Group's Fund structures include:

Funds 2 & 3 – This comprises Omni Bridgeway (Fund 2) Pty Ltd and Omni Bridgeway (Fund 3) Pty Ltd and IMF Bentham ROW SPV 1 Limited and IMF Bentham ROW SPV 2 Limited. These entities jointly invest in litigation investments outside the United States. Funds 2&3 are consolidated into the Group.

Fund 4 – This Fund invests in litigation investments in the United States. It consists of a series of parallel investing entities comprising Omni Bridgeway (Fund 4) Invt 1 LP; Omni Bridgeway (Fund 4) Invt 2 LP; Omni Bridgeway (Fund 4) Invt 3 LP; Omni Bridgeway (Fund 4) Invt 5 LP; Omni Bridgeway (Fund 4) Invt 5 LP; Omni Bridgeway (Fund 4) Invt 6 LP; Omni Bridgeway (Fund 4) Invt 7 LP; Omni Bridgeway (Fund 4) Invt 8 LP; Omni Bridgeway (Fund 4) Invt 9 LP; Security Finance (Fund 4) LLC; JPV I LP and Omni Bridgeway (Fund 4) S2 LP. Fund 4 entities are consolidated into the Group. On 8 December 2023, the Group completed the sale of a 25% interest in a portfolio of 15 intellectual property (IP) investments in Fund 4 to an affiliate of GLS Capital Partners Fund II, LP for an initial amount of US\$21.5 million, representing a multiple on invested capital (MOIC) of 2.0x of the apportioned aggregated deployments to date.

Fund 5 – Consists of a collective investment group comprising Omni Bridgeway (Fund 5) LP, Omni Bridgeway (Fund 5) Cayman Invt. Limited, Omni Bridgeway (Fund 5) Australian Invt Pty Ltd, Omni Bridgeway (Fund 5) Canada Investments Ltd, Omni Bridgeway (Fund 5) NZ Invt Limited, Omni Bridgeway (Fund 5) S2 GP Limited (formerly Omni Bridgeway (Fund 5) Cayman DDI Limited), Omni Bridgeway (Fund 5) S2 Cayman Invt Limited (formerly Gold Road Limited), Oak Henge Limited, Omni Bridgeway (Fund 5) S2 Australian Invt. Pty Ltd, Omni Bridgeway (Fund 5) S2 LP as well as parallel joint investor, Omni Bridgeway (Fund 5) GPA Pty Ltd. This Fund invests in litigation investments outside the United States. Only the parallel joint investor is consolidated within the Group and included in the segment note.

Fund 6 – Is an investment structure focused in Europe, Middle East and Africa that was acquired in a business combination on 8 November 2019 and includes the entity responsible for providing the management of Fund 7. It was established to invest in litigation, arbitration and enforcement proceedings, and for the work-out and monetisation of claims. Revenue is derived from enforcement and recovery services and other income is derived from litigation investments. OBL retains control and ownership of Fund 6 via its equity interests. Legal ownership of the litigation investments are spread across the entire OBE Group. Fund 6 is consolidated into the Group.

Fund 8 - is an investment structure focused on global enforcement investments and comprises Omni Bridgeway (Fund 8) Guernsey Investments Limited; Omni Bridgeway (Fund 8) Delaware SPV LLC; Omni Bridgeway (Fund 8) Guernsey SPV Limited; Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 1; Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 2; Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 3. Fund 8 is consolidated into the Group.

For Funds 2 & 3, the non-controlling interest is comprised of equity interests which carry an entitlement to receive a capped priority return on drawn capital and a further preferred return on committed but undrawn capital. OBL retains control and ownership of the Funds via its equity interests. Upon satisfaction of the non-controlling interests' priority returns, OBL is entitled to a manager return. After satisfaction of the priority return and the manager returns, the residual net cash flows are to be distributed 80% to OBL and 20% to non-controlling interests. The Funds have an infinite life and all distributions are discretionary.

For Fund 4 the non-controlling interest is comprised of an equity interest which, together with OBL's interest, carries an entitlement to receive return of capital plus a hurdle return on invested capital; and a pro-rata share of any residual after OBL's periodic management fee and transactional based performance fee. OBL retains control and ownership of the Funds via its equity interest. The Fund has an infinite life and all distributions are discretionary.

for the half year ended 31 December 2023 (continued)

Note 1: Segment Information (continued)

For Fund 5, there is no non-controlling interest as only OBL's 100% owned investment vehicle is consolidated. OBL's owned vehicle represents 20% of the total Fund 5 structure from which OBL is entitled to periodic management fees and transactional based performance fees.

For Fund 6, the non-controlling interest is comprised of an equity interest which, together with OBL's interest, carries a case by case entitlement to receive return of capital plus a return on invested capital after OBL's transactional based performance fee. OBL retains control and ownership of the Funds via its equity interest. The Fund has an infinite life and all distributions are discretionary during the investment period.

For Fund 8, there is no non-controlling interests as the fund is structured as an insured, leveraged special purpose vehicle (SPV). The capital for the fund is sourced from limited recourse debt.

Inter-segment revenue comprises interest revenue on intercompany loans and advisory fees.

intercompany interest revenue is recognised in accordance with AASB 9 using the effective interest rate method.

Adjustments and eliminations relate to certain finance and overheads costs that are not allocated to individual segments as the underlying expenses are incurred within wholly owned operations. These costs are capitalised into litigation funding contracts on consolidation of the Group. The associated tax effect accounting for these items is also managed on a Group basis and not allocated to the individual segments.

Inter-segment revenues and expenses are eliminated on consolidation and reflected in the "adjustments and eliminations" column.

Adjustments made in the balance sheet include adjustments to non-current assets to eliminate intercompany loans and investments in subsidiaries on consolidation.

	Cuarra			Func	ام			Consoli	alastia u
	Group			Func	15			Conson	dation
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	8 \$'000	Adjustments and eliminations \$'000	Consolidated \$'000
Segment result for half-year ended 31 December 2023									
Revenue from contracts with customers	7,180	-	_	-	-	3,148	3,452	(1,551)	12,229
Interest revenue on cash and deposits	1,382	-	198	219	4	-	-	_	1,803
Interest revenue on receivables	-	-	406	127	-	(118)	-	_	415
Interest revenue on litigation investments - purchased claims	-	-	1,182	-	-	-	-	-	1,182
Inter-segment	19,324	-	-	-	-	(62)	-	(19,262)	-
Segment revenue	27,886	-	1,786	346	4	2,968	3,452	(20,813)	15,629
Net gain/(loss) on derecognition of litigation investments - intangible assets	(569)	-	2,570	45,788	804	5,905	-	-	54,498
Derecognition of capitalised overheads on litigation investments - intangible assets	-	-	(318)	(8,003)	(564)	-	-	-	(8,885)
Net gain/(loss) on disposal of litigation investments - purchased claims	-	-	-	-	-	(82)	-	-	(82)
Net gain on deconsolidation of subsidiaries	(12,082)	-	-	85,231	-	-	-	-	73,149
Other income	392	_	136	_	-	4	996	_	1,528
Total Income	15,627	-	4,174	123,362	244	8,795	4,448	(20,813)	135,837
Amortisation of litigation investments - claims portfolio	-	-	-	-	-	4,068	(23)	-	4,045
Impairment expense and adverse costs - litigation investments	-	-	6,049	22,549	4,285	5,561	-	-	38,444
Other expenses	77,050	-	31	5,103	1,709	6,916	760	(36,927)	54,642
Share of (profit)/loss in associates	6,026	-	-	2,187	-	-	-	_	8,213
Profit/(Loss) before tax and fair value	(67,449)	-	(1,906)	93,523	(5,750)	(7,750)	3,711	16,114	30,493
Profit/(Loss) on fair value adjustment of financial assets and liabilities	1,076	-	(805)	-	-	-	-	711	982
Profit/(Loss) before tax	(66,373)	-	(2,711)	93,523	(5,750)	(7,750)	3,711	16,825	31,475
Income tax (benefit)/expense	(15,449)	-	(1,192)	(8)	(2,569)	(2,164)	-	19,500	(1,882)
Segment result	(50,924)		(1,519)	93,531	(3,181)	(5,586)	3,711	(2,675)	33,357
Attributable to:									
Equity holders of the Parent	(50,924)	-	(1,519)	9,693	(3,181)	(2,732)	3,711	(2,675)	(47,627)
Non-controlling interests	-	_	_	83,838	_	(2,854)	_	-	80,984

Note 1: Segment Information (continued)

	Group			Fun	ds			Consoli	dation
					_			Adjustments and	
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	\$ \$'000	eliminations \$'000	Consolidated \$'000
Segment assets and liabilities at 31									
December 2023									
Cash and cash equivalents ¹	80,852	-	6,004	41,700	-	4,290	-	_	132,846
Receivables due from the completion of litigation investments	f 1,521	-	36,296	34,486	-	34,660	2,675	-	109,638
Other current assets	45,732	-	2,752	3,750	10,207	20,527	2,419	(34,781)	50,606
Litigation investments - claims portfolio	1	-	-	-	-	126,111	1,460	3,728	131,300
Litigation investments - purchased claims	-	-	14,098	13,819	-	19,527	-	-	47,444
Litigation investments - intangible asset	s 10,940	-	92,033	113,896	36,183	61,877	-	35,251	350,180
Litigation investments - financial assets Litigation investments - investment in	-	-	-	10,318	7,411	-	-	(3,834)	13,895
associates Litigation investments - provision for	38,467	-	-	114,811	-	-	-	3,670	156,948
impairment	_	-	(5,507)	(30,005)	(1,593)	(3,663)	_	(4,258)	(45,026)
Goodwill	102,062	-	_	_	_	_	_	_	102,062
Investments in funds	261,185	_	_	_	_	28	_	(253,752)	7,461
Other non-current assets	431,789	-	7,087	-	1,061	20	15,078	(334,688)	120,347
Total segment assets	972,549	-	152,763	302,775	53,269	263,377	21,632	(588,664)	1,177,701
Current liabilities	93,736	_	9,732	7,274	53,555	13,347	2,279	(79,369)	100,554
Non-current liabilities	203,048	_	5,625	· _	_	14,395	11,502	27,993	262,563
Total segment liabilities	296,784	-	15,357	7,274	53,555	27,742	13,781	(51,376)	363,117
Net assets	675,765	-	137,406	295,501	(286)	235,635	7,851	(537,288)	814,584
Equity attributable to:									
Equity holders of the Parent	675,765	-	28,547	59,100	(286)	63,693	7,851	(541,809)	292,861
Contributed equity - NCI	-	-	85,292	207,019	-	154,240	-	-	446,551
Earnings - NCI	_	_	23,567	29,382	-	17,702	_	4,521	75,172
//Total equity	675,765	_							

Cash in Funds can only be used for litigation investments and expenses within the respective Funds in accordance within their mandates and constituent documents.

Note 1: Segment Information (continued)

	Group Funds Consolid		idation						
	Corporate	1	2&3	4	5	6	8	Adjustments and eliminations	Consolidate
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'00
Segment result for half-year ended 31 December 2022									
Revenue from contracts with customers	2,621	-	-	-	-	3,376	-	_	5,99
Interest revenue on cash and deposits	579	4	147	-	-	-	-	_	73
Interest revenue on receivables	-	-	1,230	-	-	95	-	_	1,32
Interest revenue on litigation investments - purchased claims	-	-	2,104	235	-	633	-	-	2,97
Inter-segment	16,039	-	-	-	-	(153)	-	(15,886)	
Segment revenue	19,239	4	3,481	235	-	3,951	-	(15,886)	11,02
Net gain/(loss) on derecognition of litigation investments - intangible assets	1,793	(6,781)	1,774	8,585	2,119	1,985	-	-	9,47
Derecognition of capitalised overheads on litigation investments - intangible assets	_	(6,965)	(568)	(547)	(200)	-	-	-	(8,28
Net gain/(loss) on disposal of litigation investments - purchased claims	-	6,376	-	-	-	-	-	-	6,37
Other income	20	_	951	_	_	_	_	_	97
Total Income	21,052	(7,366)	5,638	8,273	1,919	5,936	-	(15,886)	19,56
Amortisation of litigation investments - claims portfolio	-	-	-	-	-	2,727	-	-	2,72
Impairment expense - litigation	175	(4,759)	3,347	(1,129)	_	1,510	_	_	(85
Other expenses	78,362	43	3,204	133	348	8,190	44	(27,914)	62,41
Share of (profit) in associates and joint ventures	270	(1,607)	-	-	-	-	-	-	(1,33
Profit/(Loss) before tax and fair value	(57,755)	(1,043)	(913)	9,269	1,571	(6,491)	(44)	12,028	(43,37
Profit/(Loss) on fair value adjustment of financial liabilities	(91)	-	295	_	_	-	-	(225)	(2
Profit/(Loss) before tax	(57,846)	(1,043)	(618)	9,269	1,571	(6,491)	(44)	11,803	(43,39
Income tax (benefit)/expense	(16,362)	-	469	9	888	431	-	1,302	(13,26
Segment result	(41,484)	(1,043)	(1,087)	9,260	683	(6,922)	(44)	10,501	(30,13
Attributable to:									
Equity holders of the Parent Non-controlling interests	(41,484)	(6,546)	(1,087)	1,448	683	(6,264)	(44)	10,501	(42,79
	_	5,503	_	7,812	_	(658)	_	-	12,65

Note 1: Segment Information (continued)

	Group			Fund	ds			Consoli	dation
	Corporate \$'000	1 \$'000	2&3 \$'000	4 \$'000	5 \$'000	6 \$'000	8 \$'000	Adjustments and eliminations \$'000	Consolidated
Segment assets and liabilities at 30 June 2023									
Cash and cash equivalents ¹	92,602	_	14,655	8,175	_	1,566	18	_	117,016
Receivables due from the completion of litigation investments	36,571	-	47,131	17,094	-	44,902	-	-	145,698
Other current assets	13,934	_	7,149	1,609	15,381	22,482	1,051	(12,781)	48,825
Litigation investments - claims portfolio	_	-	-	-	-	122,118	-	3,657	125,775
Litigation investments - purchased claims	-	-	11,751	16,318	-	9,354	-	-	37,423
Litigation investments - intangible assets	9,460	-	81,096	172,763	29,073	64,341	-	29,577	386,310
Litigation investments - financial assets	_	-	-	3,777	7,199	-	-	(3,898)	7,078
Litigation investments - investment in associates	52,559	-	-	_	-	-	-	3,777	56,336
Litigation investments - provision for impairment	_	-	(556)	(11,589)	-	(3,354)	-	(726)	(16,225
Goodwill	103,304	-	-	-	-	-	-	-	103,304
Investments in funds	257,160	-	-	-	-	30	-	(250,178)	7,012
Other non-current assets	415,427	_	2,551	949	1,670	4,211	12,836	(321,361)	116,283
Total segment assets	981,017	-	163,777	209,096	53,323	265,650	13,905	(551,933)	1,134,835
Current liabilities	58,026	-	15,645	14,695	46,485	15,964	11,468	(58,556)	103,727
Non-current liabilities	212,645	-	5,065	-	522	19,948	2,975	5,667	246,822
Total segment liabilities	270,671	-	20,710	14,695	47,007	35,912	14,443	(52,889)	350,549
Net assets	710,346	-	143,067	194,401	6,316	229,738	(538)	(499,044)	784,286
Equity attributable to:									
Equity holders of the parent	710,346	-	24,750	38,880	6,316	66,946	(538)	(497,849)	348,851
Contributed equity - NCI	-	-	83,968	192,519	-	142,237	-	-	418,724
Earnings - NCI		_	34,349	(36,998)	_	20,555	_	(1,195)	16,711
Total equity	710,346	_	143,067	194,401	6,316	229,738	(538)	(499,044)	784,286

for the half year ended 31 December 2023 (continued)

Note 2: Revenue from contracts with customers

	Corporate	Fund 6	Fund 8	Tota
	\$'000	\$'000	\$'000	\$'000
Half-year ended 31 December 2023				
Type of service		2.002	2.452	6 521
Litigation investments - claims portfolio ¹	-	3,083	3,452	6,535
Management and service fees²	5,629 5,629	65 3,148	 3,452	5,69 ⁴ 12,229
Half-year ended 31 December 2022	3,023	3,110	3,132	,
Type of service				
Litigation investments - claims portfolio ¹	_	2,534	_	2,534
Management and service fees ²	2,621	842	_	3,46
	2,621	3,376	_	5,99 ⁻
Half-year ended 31 December 2023				
Geographical markets				
Europe	-	3,148	3,452	6,600
Australia	3,347	-	-	3,34
United States	1,243	-	-	1,24
Cayman Islands	1,039	-	-	1,03
_	5,629	3,148	3,452	12,22
Half-year ended 31 December 2022				
Geographical markets				
Europe	-	3,376	-	3,37
Australia	666	-	-	66
United States	1,354	-	-	1,35
Cayman Islands	601	_	_	60
_	2,621	3,376	-	5,99
This represents revenue generated from services transferred at a point in time.				
2. This represents revenue generated from services transferred over time.				

for the half year ended 31 December 2023 (continued)

Note 3: Interest revenue

	Consoli	dated
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Interest revenue		
Interest revenue on cash and deposits	1,803	730
Interest revenue on receivables	415	1,325
Interest revenue on litigation investments - purchased claims	1,182	2,972
	3,400	5,027

Note 4: Net gain on derecognition of litigation investments - intangible assets

Net gain on derecognition of litigation investments - intangible assets is derived from the disposal through sale or completion (partial or full) of the underlying litigation that the Group invested in.

	Consol	idated
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Net gain on derecognition of litigation investments - intangible assets		
Proceeds	98,308	41,073
Derecognition of carrying cost	(52,695)	(39,878)
	45,613	1,195

Derecognition of carrying cost	(52,695)	(39,878)
	45,613	1,195
Net gain on derecognition of litigation investments - intangible assets can be represented geographically as fo	ollows:	
	Consolidate	ed
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Australia	(1,547)	1,404
United States	37,752	(5,670)
Canada	(210)	(164)
EMEA	6,522	3,455
Asia	3,101	2,125
Latin America	(5)	45
	45,613	1,195

Note 5: Expenses

		Consolidated	
		31-Dec-23	31-Dec-22
		\$'000	\$'000
(a)	Finance costs		
	Interest on lease liabilities	220	153
	Other finance charges	242	2,483
		462	2,636
(b)	Amortisation of litigation investments - claims portfolio		
	Amortisation of litigation investments - claims portfolio (Note 9)	4,045	2,727
(c)	Depreciation expense		
	Depreciation of property, plant & equipment	2,200	1,950
(d)	Employee benefits expense		
997	Wages and salaries	27,309	31,355
	Superannuation expense	1,384	1,198
	Directors' fees	230	283
	Payroll tax	1,729	1,257
	Share based payments	3,802	4,893
	Long service leave	(95)	47 39,033
(e)	Corporate and office expense		
	Insurance expense	2,571	1,868
	Network expense	934	938
	Marketing expense	609	894
	Occupancy expense	407	312
	Professional fee expense	3,499	2,417
	Recruitment expense	191	962
	Travel expense	796	1,244
	naver expense	9,007	8,635
(f)	Other expenses	9,007	0,033
	ASX listing fees	63	124
	General expenses	826	908
	Amortisation of contract costs	470	470
	Postage, printing and stationary	760	821
	Repairs and maintenance	2	2
	Share registry costs	26	6
	Staff training, development and conferences	34	531
	Net foreign exchange loss	2,328	601
	Expected credit loss – receivables	4,105	2,112
	Enpected disastings in ceedings in	8,614	5,575
(g)	Impairment expense and adverse costs - litigation investments		
	Adverse costs - litigation investments (Note 20)	1,673	4,581
	Net impairment expense/(gain) - litigation investments	36,771	(856)
		38,444	3,725

for the half year ended 31 December 2023 (continued)

Note 6: Income tax

A reconciliation between tax expense/(benefit) and the product of accounting profit/(loss) before income multiplied by the Group's applicable income tax rate is as follows:

	Consolidate	d
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Accounting profit/(loss) before income tax	31,475	(43,399)
At the Group's statutory income tax rate of 30% (2023: 30%)	9,443	(13,020)
Foreign tax rate adjustments	(1,714)	596
Adjustment in respect of income and deferred tax of previous years	1,287	(261)
Non-assessable income	(10,031)	(3,710)
Non-deductible expenditures	1,304	500
Relating to deductible temporary differences not previously recognised	-	-
Write off of non-recoverable Deferred Tax Assets	153	36
Other	(2,324)	2,596
Income tax expense/(benefit) reported in the Statement of Comprehensive Income	(1,882)	(13,263)

Unrecognised temporary differences and tax losses

At 31 December 2023, the Group had \$2.1 million (30 June 2023: \$2.5 million) of unrecognised deferred tax assets relating to temporary differences and tax losses in its Canadian subsidiaries.

Deferred tax assets relating to Australian operations

The deferred tax assets balance includes \$41.9 million (30 June 2023: \$34.3 million) of assets relating to carried forward tax losses of Omni Bridgeway Limited (OBL) tax consolidated group as at 31 December 2023.

t is probable that the OBL tax group will earn sufficient taxable income to utilise the losses as the Australian business has significant investments on balance sheet and through Fund 5 participation, which have a combined EPV of \$10 billion. In addition, OBL is expected to receive distributions from Funds 2&3 and intra group income from the wider group.

Deferred tax assets relating to USA operations

The deferred tax assets balance includes \$20.4 million (30 June 2023: \$24.7 million) of assets relating to carried forward tax losses of Omni Bridgeway Holdings (USA) Inc. Under existing tax regulations, the losses incurred prior to financial year ended 30 June 2019 can be carried forward for 20 years and losses incurred thereafter can be carried forward indefinitely.

The US business had a history of incurring tax losses before the year ended 31 December 2023. The losses have arisen primarily from the implementation of the expansion of the administrative base in the United States to support strategic growth initiatives that are, according to plan, yet to realise their full value. Omni has considered the utilisation of these tax losses within the expanded US business and has determined that, based on approved budgets and existing case matters, it is probable that the US tax group will earn sufficient taxable income to utilise the losses. Further, in assessing the utilisation of the tax losses, Omni considers there to be convincing other evidence to support the recoverability of these tax losses including:

- The US business has continued to be in an expansion and infrastructure growth phase. Additional costs have been incurred in the business related to the expansion of activity and changes in operations to a Fund management structure. Investments in people, systems and infrastructure have been made ahead of the expected investment activity of the Funds. Fund 4 started in 2019 for an approved portfolio of commitments up to US\$500 million (of which the US business has a 20% interest) is currently in its investment commitment activity phase. With an average investment life of circa 3 years, a significant portion of the expected income is in the future. This income generation will be by way of both investment returns and fee revenues.
- The US business has raised substantial external capital over the past five years via its Fund structures. Fund 4 investors committed US\$500 million (80% external commitments). The external capital raised is the foundation of the investing activity that enables the US business to grow and generate returns to realise future taxable income. Fund 4 series II has recently launched and has raised A\$485 million from existing investors to date.
- (iii) US business committed a record level of commitments of A\$234 million last year. The commitment group supports the increased business activity, growth phase, profit generation and recovery of deferred tax assets in the future,
- (iv) There are 54 US investments as at 31 December 2023. It has been determined that the income generated by these investments, when realised, will exceed the tax losses within the US business.

Omni Bridgeway (Fund 2) Pty Limited and Omni Bridgeway (Fund 3) Pty Limited carried combined total deferred tax assets balances of \$0.2 million as at 31 December 2023 (30 June 2023: \$0.1 million), the deferred tax assets balances were predominantly related to the loss of Asian and Europe, Middle East & Africa investments during this reporting period. The Funds are 100% committed with litigation investment that are expected to generate significant taxable income in their respective tax jurisdictions in the future.

for the half year ended 31 December 2023 (continued)

Note 7: Loss per share

(a) Loss used in calculating loss per share

		Consoli	idated
\geq		31-Dec-23	31-Dec-22
		\$'000	\$'000
	For basic and diluted loss per share		
	Total net loss attributable to ordinary equity holders of the Parent	(47,627)	(42,793)

(a) Loss used in calculating loss per share		
	Consolid	dated
	31-Dec-23	31-Dec-22
	\$'000	\$'000
For basic and diluted loss per share		
Total net loss attributable to ordinary equity holders of the Parent	(47,627)	(42,793
(b) Weighted average number of shares		
	Consolid	dated
	31-Dec-23	31-Dec-22
	Number	Number
Weighted average number of ordinary shares outstanding	279,826,823	271,493,088
Effect of dilution:		
Performance rights	-	-
Variable deferred consideration shares	_	-
Weighted average number of ordinary shares	279,826,823	271,493,088
Variable deferred consideration is payable by the issue of fully paid ordinary shares in OBL. Please refer	to Note 13 and Note 19 f	for details.
These shares have not been included for tranches of Variable Deferred Consideration where the perform addition to this, the inclusion of any of these shares would be considered anti-dilutive.	nance milestones have n	ot been met. In
During the period to 31 December 2023, the performance milestones for Tranche 4 of the Variable Defe	rred Consideration have	been met. The

During the period to 31 December 2023, the performance milestones for Tranche 4 of the Variable Deferred Consideration have been met. The shares relating to this are only included in dilutive loss per ordinary share where the performance milestones have been met and they do not have an anti-dilutive effect. As at 31 December 2023, there were 7,755,446 variable deferred consideration shares calculated as meeting the performance criteria for inclusion in diluted loss per share, however these were not included due to their anti-dilutive effect.

The weighted average number of ordinary shares outstanding includes performance rights granted under the Long Term Incentive Plan only where the performance hurdles are met as at period end and they do not have an anti-dilutive effect. As at 31 December 2023, there were no performance rights calculated meeting the performance criteria for inclusion in diluted loss per share.

There have been no transactions involving ordinary shares or potential ordinary shares that would significantly change the number of ordinary shares outstanding between the reporting date and the date of completion of these financial statements.

Note 8: Dividends paid and proposed by Omni Bridgeway Limited (the Parent)

Cash dividends on ordinary shares declared and paid

There were no dividends declared or paid for the period ended 31 December 2023 to the equity holders of the parent.

The Company considers all its capital management options in light the cash position and performance of the Group at the time as well as the likely demand for cash over the ensuing 12-month period. In determining the appropriate mechanism to deliver returns to shareholders, the board will consider both semi-annual dividends and share buy-backs. Relevant considerations include the source and nature of income and the prevailing share price relative to the intrinsic value and the franking credit balance.

The Company has a dividend reinvestment plan (DRP) that shareholders may elect to participate in. On appropriate occasions, the Company may arrange DRP underwriting to reduce the impact a particular dividend might otherwise have on the Group's cash resources.

for the half year ended 31 December 2023 (continued)

B. INVESTMENTS AND INTANGIBLE ASSETS

Note 9: Litigation investments - claims portfolio

	Consoli	dated
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Balance at start of the period ¹	125,775	106,123
Additions	10,692	20,969
Amortisation of carrying costs ²	(4,045)	(4,042)
Impairment loss	(1,881)	(719)
Foreign currency adjustment	759	3,444
Balance at the end of the period ³	131,300	125,775

Includes \$63.2 million (30 June 2023:\$59.6 million) of fair value adjustments from business combination in the year ended 30 June 2020. 2. Includes (\$0.8) million (30 June 2023: (\$1.2) million) of fair value adjustments from business combination in the year ended 30 June 2020. Includes \$61.6 million (30 June 2023: \$63.2 million) of fair value adjustments from business combination in the year ended 30 June 2020.

Note 10: Litigation investments - purchased claims

	Consolidate	ed
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Balance at 1 July ¹	37,423	47,040
Interest revenue	1,182	5,122
Additions	12,432	-
Increase in carrying value	781	(16,387)
Carrying value disposed ²	(94)	(651)
Impairment loss	(4,144)	(1,546)
Foreign currency adjustment	(136)	3,845
Balance at the end of the period ³	47,444	37,423
On 15 December 2023, Fund 6 acquired a portfolio of non-performing loans for a transaction price of \$12.4 m		
on 15 becember 2023, Fulla o acquirea a portiono of non-performing loans for a transaction price of \$12.4111	llion. Consolidate	ed
-		ad 31-Dec-22
-	Consolidate	
Net loss on disposal of litigation investments - purchased claims	Consolidate 31-Dec-23	31-Dec-22
	Consolidate 31-Dec-23	31-Dec-22
Net loss on disposal of litigation investments - purchased claims	Consolidate 31-Dec-23 \$'000	31-Dec-22
Net loss on disposal of litigation investments - purchased claims Proceeds	Consolidate 31-Dec-23 \$'000	31-Dec-22

	Consoli	dated
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Net loss on disposal of litigation investments - purchased claims		
Proceeds	12	_
Carrying value disposed ²	(94)	-
	(82)	_

- Includes \$nil (30 June 2023: \$0.2 million) of fair value adjustments from the business combination in the year ending 30 June 2020.
- Include \$0.9 million (30 June 2023: \$0.9 million) of fair value adjustments from the business combination in the year ending 30 June 2020.

for the half year ended 31 December 2023 (continued)

Note 11: Litigation investments - intangible assets

(a) Reconciliation of carrying amounts

The carrying value of litigation investments - intangible assets can be summarised as follows:

	Consolidate	ed
	31-Dec-23	30-Jun-23
	\$'000	\$'000
External funding costs	291,995	337,167
Capitalised overheads	58,187	49,143
Gross carrying amount at cost	350,182	386,310
Accumulated impairment	(45,028)	(16,225)
Net carrying amount	305,154	370,085

Included in the closing balance is \$17.7 million (30 June 2023: \$18.1 million) of purchase price adjustments that originally arose from business combination.

(b) Impairment testing of litigation investments - intangible assets

Except for specific litigation investments – intangible assets that are subject to an unfavourable judgement or award, the recoverable amount of each of the litigation investments – intangible assets is determined based on a value in use calculation using cash flow projections based on financial budgets approved by management for the expected length of each investment.

The following describes each key assumption on which management has based its cash flow projections when determining the value in use of litigation investments - intangible assets:

The estimated cost to complete is budgeted based on estimates provided by the external legal advisors handling the litigation.

The value to the Group, once completed, is estimated based on the successful conclusion and the resulting expected settlement or judgment amount of the litigation and the fees due to the Group under the litigation funding contract.

The discount rate of 12% applied to the cash flow projections is based on the Group's weighted average cost of capital and other factors relevant to the particular investment including country risk.

At 31 December 2023, the balance of provisions for impairment was \$45.0 million (30 June 2023: \$16.2 million). The \$28.8 million net movement in the period reflects:

- (i) \$31.9 million of new impairments in relation to 19 investments;
- (ii) the net impact of investment and the asset derecognised; and
- (iii) foreign exchange variances.

For new or increased impairments, during the impairment review, management have determined that either a successful outcome for the investment was no longer likely to occur or that the likely outcome would not recover the current carrying value of the investment. The discount rate used in the impairment indicator assessment of these assets was 12%. After taking into account the impairment indicators, at 31 December 2023, the 19 investments have a combined carrying value of \$13.8 million. This amount reflects the net recoverable amount expected to be received from the investments.

for the half year ended 31 December 2023 (continued)

Note 12: Investment in associates

		Consol	idated	
	Litigation Inve Investment in		Othe	rs
	31-Dec-23	30-Jun-23	31-Dec-23	30-Jun-23
	\$'000	\$'000	\$'000	\$'000
Balance at 1 July	56,336	-	6,981	5,031
Additions (Note 23)	116,997	56,336	600	1,280
Adjustment	(6,650)	_	-	_
Share of (Loss)/Profit	(8,148)	_	(65)	555
Foreign currency adjustment	(1,587)	-	(83)	115
Balance at the end of the period	156,948	56,336	7,433	6,981

The above balances and movements includes secondary market sales that occurred including the Fund 1 sale in May 2023 and the partial sale of the US IP portfolio in the current period. On deconsolidation, OBL's residual interest within these entities are measured at the present value of probabilistic cash flows and subsequently accounted for under equity accounting. Refer to Note 23 for further information on the current period transaction.

The current period transaction resulted in a net gain on deconsolidation of subsidiaries amounted \$73.1 million, including a net gain from deconsolidation of Omni Bridgeway (Fund 4) Eagle SPV LLC of \$79.8 million (refer to Note 23) and an adjustment on initial recognition of Omni Bridgeway (Fund 1) LLC of \$6.7 million.

Included in "Others" is OB Capital Coop U.A, which is an associate of the Group and was acquired through the acquisition of Omni Bridgeway Holding B.V. in November 2019. The entity invests in litigation investments in the Netherlands. The Coop agreement outlines the various powers and rights of responsibilities of the members, includes provisions that provide the Group with significant influence over the entity.

for the half year ended 31 December 2023 (continued)

C. CAPITAL STRUCTURE

Note 13: Financial risk management

The value of the Group's financial assets and liabilities will be impacted by changes in interest rates and foreign exchange rates. The carrying amount of the financial assets and liabilities of the Group approximate their fair values.

Fair values

The carrying amounts of financial assets and liabilities of the Group carried at amortised cost approximate their fair values.

For the purposes of disclosure, the fair value measurements used for all assets and liabilities below are level 3.

	Carrying A	mount	Fair V	alue
	31-Dec-23	30-Jun-23	31-Dec-23	30-Jun-23
	\$'000	\$'000	\$'000	\$'000
Financial assets				
Receivables from litigation contracts and other	147,038	186,431	147,038	186,431
Litigation investments - purchased claims	47,444	37,423	47,444	37,423
Financial investments	13,895	7,078	13,895	7,078
Security deposits	3,019	2,925	3,019	2,925
	211,396	233,857	211,396	233,857
Financial liabilities				
Trade and other payables	48,041	50,110	48,041	50,110
Borrowings	182,616	181,639	182,616	181,639
Deferred consideration	2,984	4,074	2,984	4,074
Variable deferred consideration – business combination	9,513	14,773	9,513	14,773
Variable consideration – litigation investments - purchased claims	8,211	7,667	8,211	7,667
	251,365	258,263	251,365	258,263

Variable deferred consideration - business combination

The significant inputs used in the fair value measurements of deferred and variable deferred consideration – business combination, categorised within Level 3 of the fair value hierarchy, together with a quantitative sensitivity analysis as at 31 December 2023 are shown below:

Item	Valuation technique	Significant unobservable inputs	Range (weighted average)	Sensitivity of the input to fair value
Variable deferred consideration	Black Scholes Option Pricing	Exercise price	Theoretical exercise price based on the floor price of \$3.407	
	Model	Volatility	45% at 31 December 2023 and 40% at 30 June 2023	At 31 December 2023: An absolute 5% increase in the volatility would result in a \$10,000 increase in the value of the liability. An absolute 5% decrease in the volatility would result in a \$6,000 decrease in the value of the liability.
				At 30 June 2023: An absolute 5% increase in the volatility would result in a \$170,000 increase in the value of the liability. An absolute 5% decrease in the volatility would result in a \$164,000 decrease in the value of the liability.
		Underlying share price	\$1.355 at 31 December 2023 and \$2.62 at 30 June 2023	At 31 December 2023: A relative 5% increase in the share price would result in a \$6,000 increase in the value of the liability. A relative 5% decrease in the share price would result in a \$2,000 decrease in the value of the liability.
				At 30 June 2023: A relative 5% increase in the share price would result in a \$176,000 increase in the value of the liability. A relative 5% decrease in the share price would result in a \$153,000 decrease in the value of the liability.

Note 13: Financial risk management (continued)

Variable deferred Scholes Option (continued) Scholes Option (continued) Pricing Model (continued) Risk free rate At 31 December 2023: At 30 June 2023: Offor 8-Nov-24 payment At 31 December 2023: At 30 June 2023: At 31 December 2023: At 30 June 2023: At 30 June 2023: At 30 June 2023: At 31 December 2023: At 30 June 2023: At 30 June 2023: At 31 December 2023: At 30 June 2023: At 31 December 2023: At 30 June 2023: At 31 December 2023: At 30 June 2023: At 31 December 2023: At 30 June 2023: A	Item	Valuation technique	Significant unobservable inputs	Range (weighted average)	Sensitivity of the input to fair value		
At 30 June 2023: 0% for 8-Nov-23 payment; 0% for 8-Nov-24 payment Risk free rate At 31 December 2023: 4.1% for 8-Nov-24 payment At 30 June 2023: 4.1% for 8-Nov-24 payment At 30 June 2023: 4.1% for 8-Nov-24 payment At 31 December 2023: An absolute 0.5% increase in risk free rate would result in a \$28,000 increase in the value of liability. At 30 June 2023: 4.36% for 8-Nov-23 payment; 4.36% for 8-Nov-24 payment; 4.	deferred consideration	Scholes Option Pricing	Dividend yield	2023: 0% for 8-Nov-24	An absolute 1% increase in dividend yield wou decrease in the value of the liability. An absoludividend yield would result in a \$0 increase in the substitution of the	te 1% de	crease in
An absolute 0.5% increase in risk free rate would result in a \$2 decrease in the value of the liability. An absolute 0.5% decrease risk free rate would result in a \$28,000 increase in the value of liability. At 30 June 2023: 4.36% for 8-Nov-23 payment; 4.36% for 8-Nov-24 payment; FX forward rate (AUD/ EUR) At 31 December 2023: Arelative 5% increase/(decrease) in the forward exchange rate would result in a \$335,000 increase/(decrease) in the value of the liability.		(continued)		0% for 8-Nov-23 payment; 0% for 8-	At 30 June 2023: An absolute 1% increase in dividend yield would redecrease in the value of the liability. An absolute 1	% decreas	\$33,000 se in dividei
At 30 June 2023: 4.36% for 8-Nov-23 payment; 4.36% for 8-Nov-24 payment; 8-Nov-24 payment; At 30 June 2023: At 30 June 2023: An absolute 0.5% increase in risk free rate would result in a \$43,00 decrease in the value of the liability. An absolute 0.5% decrease in the value of the liability.			Risk free rate	2023: 4.1% for 8-Nov-24	An absolute 0.5% increase in risk free rate wou decrease in the value of the liability. An absolu risk free rate would result in a \$28,000 increase	te 0.5% d	lecrease in
rate (AUD/ 2023: A relative 5% increase/(decrease) in the forward exchange rate would result in a \$335,000 increase/(decrease) in the value of the v				4.36% for 8-Nov-23 payment; 4.36% for	At 30 June 2023: An absolute 0.5% increase in risk free rate would r decrease in the value of the liability. An absolute 0	.5% decre	ease in risk
			rate (AUD/	2023:	A relative 5% increase/(decrease) in the forward would result in a \$335,000 increase/(decrease)		
At 30 June 2023: 8-Nov-23: 1.64 8-Nov-24:1.66 At 30 June 2023: A relative 5% increase/(decrease) in the forward exchange rates we result in a \$714,000 increase/(decrease) in the value of the liability.				8-Nov-23: 1.64	A relative 5% increase/(decrease) in the forward ex		
Consolidated))						30-Jun \$'(
31-Dec-23 30-j	Cash at bank						115,4
31-Dec-23 30-J \$'000	Cl	posits			2,	702	1,58
Cash at bank 31-Dec-23 30-J	Snort-term de						

<u></u>	Consoli	idated
-	31-Dec-23	30-Jun-23
<u> </u>	\$'000	\$'000
Cash at bank	130,144	115,430
Short-term deposits	2,702	1,586
	132,846	117,016

Bank guarantees

Bank guarantees have been issued by the Group's bankers as security for leases over premises and banking facilities. As at 31 December 2023, guarantees of \$1.8 million were outstanding (30 June 2023: \$1.7 million). The Group has a total guarantee facility limit of \$1.8 million (30 June 2023: \$1.7 million) that is secured by an offset arrangement with deposits of \$1.6 million (30 June 2023: \$1.5 million).

for the half year ended 31 December 2023 (continued)

Note 15: Borrowings

	Consolidated	
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Non-Current		
Senior Facility	182,616	181,639
Borrowings - Fund 8	9,449	_
	192,065	181,639

The total amount of drawn down from debt facility at 31 December 2023 was \$190.0 million (30 June 2023: \$190.0 million). The facility terms include a variable rate of interest based on the BBSW Bid rate plus a fixed margin of 7.00% per annum, a maturity date of 1 July 2027.

During the half year ended 31 December 2023, Fund 8 entered into the first tranche of its debt capital with an investment vehicle owned by funds managed by affiliates of Fortress Investment Group for €135.0 million. Capital loss in Fund 8 is insured pursuant to a principal protection nsurance indemnity of an initial amount of €135.0 million. The debt facility and the insurance provide for a four-year investment based on a commencement date of 21 August 2023. During the investment period and a subsequent four-year harvest period, all investment proceeds are applied against the outstanding debt balance. As of 31 December 2023, \$10.1 million were drawn down from Fund 8 debt facility.

 ${f j}$ he Group complied with the financial and non-financial covenants throughout the reporting period.

Note 16: Contributed equity

	Consol	idated
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Contributed equity		
ssued and fully paid ordinary shares	462,253	449,854

		<u>—</u>	Consolidate	ed
			31-Dec-23	30-Jun-23
			\$'000	\$'000
Contributed equity				
ssued and fully paid ordinary shares			462,253	449,85
(a) Ordinary shares				
Fully paid ordinary shares carry one vote per share and carry the right to	dividends			
Tally paid ordinary shares carry one vote per share and carry the right to	dividerius.			
		Consolidat	ed	
	Period ended 31	-Dec-23	Year ended 30-	Jun-23
115)	Number		Number	
	000	\$'000	000	\$'00
Movement in ordinary shares				
Balance at 1 July	278,619	449,854	268,639	406,96
Shares issued during the period (deferred and variable deferred consideration)	-	-	7,756	30,71
Shares issued upon exercise of performance rights	1,852	12,399	2,768	13,83
Share Buy-Back Scheme	-	_	(544)	(1,66
Balance at period end	280,471	462,253	278,619	449,85
-				
(b) Performance rights				
At 31 December 2023, there were 12,421,755 unissued ordinary shares i	n respect of outstand	ing share perform	ance rights (30 Jun	e 2023:
15,421,416).				

for the half year ended 31 December 2023 (continued)

D. WORKING CAPITAL, OTHER ASSETS AND OTHER LIABILITIES

Note 17: Trade and other receivables

Receivables are recognised initially at the present value of owed amount and subsequently remeasured at amortised cost using the effective interest rate method, less an allowance for any uncollectible amounts.

Receivables due from the completion of litigation investments are recognised upon various stages of completion of the underlying litigation in conjunction with the income recognition criteria of each investment. Collectability is reviewed on an ongoing basis and at each reporting period.

The Group recognises an allowance for expected credit losses (ECLs) for all receivables based on the difference between the contractual cash flows due and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

Other receivables comprise interest receivable upon the maturity of the Group's short-term deposits (between 30 and 90 days), receivables from co-funders of litigation contracts in progress, short term loans and deposits receivable.

	Consoli	dated
	31-Dec-23	30-Jun-23
<u> </u>	\$'000	\$'000
Current		
Receivables from litigation contracts	66,594	101,929
Other receivables	37,395	38,841
	103,989	140,770
Non-current		
Receivables from litigation contracts	43,044	43,769
Other receivables	5	1,892
	43,049	45,661

Fair value and credit risk

Due to the nature of these receivables, the carrying value of the current and non-current receivables approximates fair value. The maximum exposure to credit risk associated with receivables is the carrying value of receivables.

Note 18: Other assets

31-Dec-23 \$'000 7,099 3,019 10,118	30-Jun-23 \$'000 5,075 2,925 8,000
7,099 3,019	5,075 2,925
3,019	2,925
3,019	2,925
10,118	8 000
	0,000
13,630	16,988
796	800
14,426	17,788
	796

for the half year ended 31 December 2023 (continued)

Note 19: Other financial liabilities

Variable deferred consideration is valued at fair value at the acquisition date as part of a fair value through profit or loss business combination. It is subsequently remeasured at fair value at each reporting date.

	Consolidated		
	31-Dec-23	30-Jun-23	
	\$'000	\$'000	
Current		_	
Deferred consideration – insurance	931	1,099	
Variable deferred consideration – business combination	9,513	6,998	
	10,444	8,097	
Non-current Non-current			
Deferred consideration – insurance	2,053	2,975	
Variable deferred consideration – business combination	_	7,775	
	2,053	10,750	

The deferred consideration - insurance relates to insurance product acquired for Funds 2&3.

Variable deferred consideration - business combination

This relates to the acquisition of OBE Group. The determination of the fair value is designated as level 3 in the fair value hierarchy. Refer to Note 13 for further information.

The following table reconciles the movements in recurring fair value measurements categorised within level 3 of the fair value hierarchy:

	Deferred consideration – business combination¹	Variable deferred consideration – business combination	Total
	\$'000	\$'000	\$'000
Current		6.009	6 000
At 1 July 2023	_	6,998	6,998
Issue of shares / Payment of cash to satisfy the liability	_	(3,558)	(3,558)
Reclassification from non-current	-	6,115	6,115
Effect of movement in foreign currency	<u>-</u> _	(42)	(42)
At 31 December 2023		9,513	9,513
Non-current			
At 1 July 2023	-	7,775	7,775
Fair value remeasurement recognised through profit or loss	-	(1,567)	(1,567)
Reclassification to current	-	(6,115)	(6,115)
Effect of movement in foreign currency		(93)	(93)
At 31 December 2023		-	-
	Deferred consideration – business combination ¹	Variable deferred consideration – business combination	Total
	\$'000	\$'000	\$'000
Current	45.404	10.670	20.464
At 1 July 2022	15,491	13,670	29,161
Fair value remeasurement recognised through profit or loss	337	(1,161)	(824)
Issue of shares to satisfy the liability	(16,297)	(14,415)	(30,712)
Reclassification from non-current	-	8,503	8,503
Effect of movement in foreign currency	469	401	870
At 30 June 2023		6,998	6,998

	Deferred consideration – business combination ¹	Variable deferred consideration – business combination	Total
	\$'000	\$'000	\$'000
Current			
At 1 July 2022	15,491	13,670	29,161
Fair value remeasurement recognised through profit or loss	337	(1,161)	(824)
Issue of shares to satisfy the liability	(16,297)	(14,415)	(30,712)
Reclassification from non-current	-	8,503	8,503
Effect of movement in foreign currency	469	401	870
At 30 June 2023		6,998	6,998
Non-current			
At 1 July 2022	-	16,568	16,568
Fair value remeasurement recognised through profit or loss	_	(1,617)	(1,617)
Reclassification to current	-	(8,503)	(8,503)
Effect of movement in foreign currency	-	1,327	1,327
At 30 June 2023	-	7,775	7,775

Deferred consideration - business combination was fully paid via shares issue in December 2022

for the half year ended 31 December 2023 (continued)

Note 20: Provisions

	Consoli	dated
	31-Dec-23	30-Jun-23
	\$'000	\$'000
Current		
Annual leave and vested long service leave	4,068	4,483
Adverse costs	27,259	26,753
Bonus	-	2
	31,327	31,238
Non-current		
Premises lease make good	621	626
Long service leave	516	665
	1,137	1,291

Annual leave and vested long service leave

Provision is made for employee benefits accumulated as a result of employees rendering services up to the end of the reporting period.

Bonus

The bonus provision relates to amounts accrued based on management's estimate to be paid to employees (including STIP).

Premises lease make good

The make good provision relates to amounts recognised for make good requirements on leases of office space.

Note 21: Commitments and contingencies

Certain litigation funding agreements entered into by a Group entity contain an undertaking to pay any adverse costs awarded should the funded party's litigation be unsuccessful. Adverse costs is the name given to the legal costs of the successful party in applicable "cost shifting" jurisdictions, which generally excludes the United States of America. Based on past experience, an award for adverse costs to a defendant will approximate 40% to 80% (depending on the jurisdiction) of the amount paid by the claimant to pursue the litigation. In cases with multiple defendants, this range can be exceeded.

The Group assesses all of its investments for the probability of having to disburse adverse costs and, when deemed necessary, records the amount expected to pay out as a provision.

Certain Group entities mitigate the risk of paying adverse costs through after the event insurance ("ATE"). In addition, "top-up" ATE insurance may be obtained for single investments to reduce adverse cost concentration risk, and to provide for additional cover.

When the Group records a provision for adverse costs that is subject to ATE insurance, an insurance receivable is correspondingly recorded for the estimate of the coverage. The provisions and insurance receivable recorded are subject to estimates that take into account the portfolio effects, and in respect of the latter, the self-insured excess and the policy indemnity amount.

At 31 December 2023, the adverse cost exposure is \$27.3 million (with Fund 5 at 20%) (refer to Note 20). Of this provision \$8.3 million is expected to be recovered from insurance or a co-funding agreement.

for the half year ended 31 December 2023 (continued)

E. THE GROUP, MANAGEMENT AND RELATED PARTIES

Note 22: Related party disclosures

Transactions with related entities

The following table provides the total amount of transactions that were entered into with related parties for the relevant periods.

	Consc	olidated
	31-Dec-23	31-Dec-22
	\$'000	\$'000
Transactions with OB DARP Cooperatief UA ¹	62	724
	62	724

^{1.} During the period, the Group received management fees from OB DARP Cooperatief UA, a related party of the Group.

Loans with a related entity

The following table provides the total amount of loans with related parties for the relevant financial period.

		Consolidated	
		31-Dec-23	30-Jun-23
		\$'000	\$'000
Loans	with Omni Bridgeway DARP Cooperatief UA	6,576	6,697
		6,576	6,697

Note 23: Composition of the Group

The Group's subsidiaries can be summarised as follows:

		Percentage Owned		
	Country of	At 31-Dec-23	At 30-Jun-23	
Name	Incorporation	%	%	
Funds 2 & 3				
Omni Bridgeway (Fund 2) Pty Ltd	Australia	29	27	
Omni Bridgeway (Fund 3) Pty Ltd	Australia	29	27	
IMF Bentham ROW SPV 1 Limited	United Kingdom	29	27	
IMF Bentham ROW SPV 2 Limited	Australia	29	27	
Fund 4				
Omni Bridgeway (Fund 4) Invt 1 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 2 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 3 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 4 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 5 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 6 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 7 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 8 LP	USA	20	20	
Omni Bridgeway (Fund 4) Invt 9 LP	USA	20	20	
JPV I LP	USA	20	20	
Omni Bridgeway (Fund 4) S2 L.P.1	USA	20	-	
Fund 5				
Omni Bridgeway (Fund 5) GPA Pty Ltd	Australia	100	100	

for the half year ended 31 December 2023 (continued)

Note 23: Composition of the Group (continued)

		Percentage	Owned
	Country of	At 31-Dec-23	At 30-Jun-23
Name	Incorporation	%	%
			81
			41
			81
= -			81
9 3	= :		81
			81
	0		81
	Germany		81
	France		81
\ = :	Netherlands	81	81
	Netherlands	N/A	N/A
	Netherlands	N/A	N/A
Stichting Trucks Cartel Compensation	Netherlands	N/A	N/A
Omni Bridgeway Italy S.r.L	Italy	81	81
FT Atlas I⁵	Morocco	N/A	N/A
Fund 7			
Omni Bridgeway Advisory Ltd	United Arab Emirates	65	65
Fund 8			
Omni Bridgeway (Fund 8) Guernsey Investments Ltd	Guernsey	81	81
\	USA	81	-
	Guernsev	81	_
	3	81	_
		81	_
			_
Simulating (Canada) Scianai e Si V EEE Scies S	33/1		
Group Subsidiaries			
Omni Bridgeway Holdings (Fund 1) LLC	USA	100	100
Security Finance (Fund 4) LLC	USA	100	100
Omni Bridgeway Capital GP (Fund 4) LLC	USA	100	100
Omni Bridgeway (USA) LLC	USA	100	100
Omni Bridgeway Management (USA) LLC	USA	100	100
Omni Bridgeway Holdings (USA) Inc	USA	100	100
	USA	100	100
-	Canada	100	100
Lien Finance Canada Limited	Canada	100	100
Omni Bridgeway (Singapore) Pte Limited	Singapore	100	100
	0 .		100
	<u> </u>		100
	Australia		100
			100
			100
9 9			100
			100
		100	
Omni Bridgeway (NZ) Limited	New Zealand	11111	100
	Fund 6 Omni Bridgeway BV Omni Bridgeway LegalTech BV Omni Bridgeway LegalTech BV Omni Bridgeway Emerging Markets BV Omni Bridgeway Collective Redress BV Omni Bridgeway Asia Pte Ltd Omni Bridgeway Asia Pte Ltd Omni Bridgeway SA Omni Bridgeway Fance SAS Omni Bridgeway France SAS Omni Bridgeway France BV Stichting Client Accounts Omni Bridgeway Stichting Cartel Compensation Stichting Trucks Cartel Compensation Omni Bridgeway Italy S.r.L FT Atlas I ⁵ Fund 7 Omni Bridgeway (Fund 8) Guernsey Investments Ltd Omni Bridgeway (Fund 8) Belaware SPV LLC² Omni Bridgeway (Fund 8) Belaware SPV LLC² Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 14 Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 24 Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 34 Group Subsidiaries Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 34 Group Subsidiaries Omni Bridgeway (Fund 4) LLC Omni Bridgeway Capital GP (Fund 4) LLC Omni Bridgeway Holdings (USA) LLC Omni Bridgeway Holdings (USA) LLC Omni Bridgeway Holdings (USA) Inc Security Finance (LC Omni Bridgeway Capital (Canada) Limited	Name Incorporation Fund 6 Netherlands Omni Bridgeway LegalTech BV Netherlands Omni Bridgeway Cenerging Markets BV Netherlands Omni Bridgeway Collective Redress BV Netherlands Omni Bridgeway Collective Redress BV Netherlands Omni Bridgeway Collective Redress BV Netherlands Omni Bridgeway Asia Pte Ltd Singapore Omni Bridgeway Broance SA Switzerland Omni Bridgeway Finance BV Netherlands Sichting Clent Accounts Omni Bridgeway Netherlands Stichting Clent Accounts Omni Bridgeway Netherlands Stichting Trucks Cartel Compensation Netherlands Smid Bridgeway Italy S.r.L Italy FT Atlas IB Morocco Fund 7 United Arab Emirates Fund 8 Guernsey Omni Bridgeway (Fund 8) Guernsey Investments Ltd Guernsey Fund Bridgeway (Fund 8) Delaware SPV LLC? USA Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 14 USA Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 24 USA Omni Bridgeway (Fund 8) Delaware SPV LLC - Series 34 <td>Name Incorporation % Fund 6 Orn's Bridgeway by Netherlands 81 Orn's Bridgeway Legalitech BV Netherlands 81 Orn's Bridgeway Legalitech BV Netherlands 81 Orn's Bridgeway Legalitech BV Netherlands 81 Orn's Bridgeway Collective Redress BV Netherlands 81 Orn's Bridgeway Collective Redress BV Netherlands 81 Orn's Bridgeway Holding (Switzerland) SA Switzerland 81 Orn's Bridgeway Holding (Switzerland) SA Switzerland 81 Orn's Bridgeway France SAS France 81 Orn's Bridgeway France BV Netherlands N/A Stichting Tuck Accounts Orn's Bridgeway Netherlands N/A Stichting Tuck Carrel Compensation Netherlands N/A Stichting Tuck Carrel Compensation Netherlands N/A Proff T Italy 81 Fund 7 Italy 81 Fund 8 United Arab Emirates 65 Fund 8 United Arab Emirates 65 <td< td=""></td<></td>	Name Incorporation % Fund 6 Orn's Bridgeway by Netherlands 81 Orn's Bridgeway Legalitech BV Netherlands 81 Orn's Bridgeway Legalitech BV Netherlands 81 Orn's Bridgeway Legalitech BV Netherlands 81 Orn's Bridgeway Collective Redress BV Netherlands 81 Orn's Bridgeway Collective Redress BV Netherlands 81 Orn's Bridgeway Holding (Switzerland) SA Switzerland 81 Orn's Bridgeway Holding (Switzerland) SA Switzerland 81 Orn's Bridgeway France SAS France 81 Orn's Bridgeway France BV Netherlands N/A Stichting Tuck Accounts Orn's Bridgeway Netherlands N/A Stichting Tuck Carrel Compensation Netherlands N/A Stichting Tuck Carrel Compensation Netherlands N/A Proff T Italy 81 Fund 7 Italy 81 Fund 8 United Arab Emirates 65 Fund 8 United Arab Emirates 65 <td< td=""></td<>

^{1.} Incorporated on 27 October 2023.

For all subsidiaries where there is less than 51% ownership interest, the Group has power to direct the relevant activities of the investee under contractual arrangements and exposure to variable returns the Group is considered to be acting as principal and thus has control.

^{2.} Incorporated on 21 July 2023.

^{3.} Incorporated on 27 July 2023.

^{4.} Incorporated on 31 July 2023.

^{5.} The Moroccan securitization special purpose vehicle was founded during the period to setup a portfolio purchased by Omni Bridgeway S.A.

for the half year ended 31 December 2023 (continued)

Note 23: Composition of the Group (continued)

Movements in NCIs of material partly owned subsidiaries during the period were as follows:

	Consolidated				
	Fund 1	Funds 2&3	Fund 4	Fund 6	Total
	\$'000	\$'000	\$'000	\$'000	\$'000
Balance at 1 July 2022	73.219	112,784	91,013	133,593	410,609
Contributions	10,548	15,880	85,390	24,036	135,854
Distributions	(34,244)	(24,950)	(33,972)	_	(93,166)
Deconsolidation of Subsidiary	(49,518)	_	_	_	(49,518)
Change in share of net assets attributable to NCI	(4,076)	2,938	(3,662)	(2,356)	(7,156)
Profit	4,071	11,416	11,870	5,164	32,521
Other comprehensive income	-	250	3,687	2,354	6,291
Balance at 30 June 2023		118,318	154,326	162,791	435,435
Contributions	-	10,400	39,619	12,003	62,022
Distributions	-	(21,621)	(37,161)	-	(58,782)
Change in share of net assets attributable to NCI	-	1,851	5,300	685	7,836
Profit/(loss)	-	-	83,838	(2,854)	80,984
Other comprehensive loss	_	(89)	(4,999)	(684)	(5,772)
Balance at 31 December 2023	_	108,859	240,923	171,941	521,723

On 8 December 2023, the Group sold a 25% interest in a portfolio of 15 intellectual property (IP) investments in Fund 4 to an affiliate of GLS Capital Partners Fund II, LP for an initial amount of \$31.5 million. The transaction resulted in the deconsolidation of the Fund 4 entity, Omni Bridgeway (Fund 4) Eagle SPV LLC by the Group because of the loss of control on the transaction date.

The residual interest in the portfolio of \$116.7 million is recognised as an investment in associate within the Group Consolidated Financial Statements. An aggregate net gain to the Group of \$74.7 million was recognised into the profit or loss, including the effect of the derecognition of related capitalised overhead costs amounted \$5.1 million.

Deconsolidation of Omni Bridgeway (Fund 4) Eagle SPV LLC:

\$'000
31,494
62,989
(31,494)
62,989
31,708
116,997
(485)
(5,432)
79,799
(5,149)
74,650

[.] The capitalised overhead costs in relation to the disposed entity were fully written off upon the deconsolidation, as part of the calculation of net gain on derecognition of litigation investments - intangible assets in the profit or loss.

for the half year ended 31 December 2023 (continued)

Note 24: Events after the reporting date

In January 2024, we received a positive appeal decision relating to a Fund 4 investment, and in February 2024, we reached settlement in two Fund 5 investments for which we anticipate recognising, in aggregate, approximately \$29 million income in 2H24.

Except as disclosed in this report there have been no other subsequent events after the reporting date that are not included in the Group Consolidated Financial Statements.

Directors' Declaration

I state that, in the directors' opinion:

 the financial statements and notes of Omni Bridgeway Limited and its controlled entities (the Group) comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements

the financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2023 and of its performance for the financial half-year ended on that date; and

there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001, on behalf of the directors.

Michael Kay

Non-Executive Chairman

28 February 2024



Tel: +61 8 6382 4600 Fax: +61 8 6382 4601 www.bdo.com.au Level 9, Mia Yellagonga Tower 2 5 Spring Street Perth WA 6000 PO Box 700 West Perth WA 6872 Australia

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Omni Bridgeway Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Omni Bridgeway Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2023, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (i) Giving a true and fair view of the Group's financial position as at 31 December 2023 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

1



Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2023 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit (WA) Pty Ltd

GATA ODATE

Glyn O'Brien

500

Director

Perth, 28 February 2024

Corporate Information

This Interim Financial Report covers Omni Bridgeway Limited and its subsidiaries. The Group's functional and presentation currency is AUD (\$).

Directors

Michael Kay Non-Executive Chairman

Andrew Saker Managing Director & CEO (retired 26 October 2023)

Raymond van Hulst Managing Director & CEO (appointed 26 October 20.)

Managing Director & CEO (appointed 26 October 2023), former Executive Director and Co-Chief Investment Officer – EMEA

Karen Phin Non-Executive Director
Christine Feldmanis Non-Executive Director
Michael Green Non-Executive Director

Joint Company Secretaries

Jeremy Sambrook

Christopher Huish

Registered office and principle place of business in Australia

Level 7, 35 Clarence Street Sydney NSW 2000

Phone: +61 2 8223 3567 Fax: +61 2 8223 3555

Solicitors

DLA PIPER

Level 9, 480 Queen Street

Brisbane QLD 4000

THOMSON GEER

Level 27, Exchange Tower 2 The Esplanade Perth WA 6000

Share Registry

COMPUTERSHARE

Level 11, 172 St Georges Terrace Perth WA 6000

Auditors

BDO AUDIT (WA) PTY LTD

Level 9

Mia Yellagonga Tower 2 5 Spring Street Perth WA 6000

Bankers

NATIONAL AUSTRALIA BANK LIMITED

2 Carrington Street Sydney NSW 2000

WESTPAC BANKING CORPORATION

275 Kent Street, Sydney NSW 2000

Internet Address

www.omnibridgeway.com

The Company is listed on the Australian Securities Exchange with Sydney, Australia as its home exchange. Its ASX code is "OBL" and its shares were trading as at the date of this report.

US ownership restriction

The ordinary shares of Omni Bridgeway are subject to ownership restrictions applying to residents of the United States. For further information, see the Investor section of our website or omnibridgeway.com/investors/us-ownership-restriction.

Glossary

_		
Α	ASB	Australian Accounting Standards Board.
С	AGR	Compound annual growth rate.
E	MEA	The geographic region incorporating Europe, Middle East and Africa where the Group invests and offers its products and services.
E	PS	Earnings per share.
P	stimated ortfolio Value EPV)	OBL's estimate of the value that may be achieved from an investment's underlying litigation from time-to-time. For an investment where the funding entity earns:
		i. a percentage of the resolution proceeds arising from the underlying litigation or enforcement as a funding commission, EPV is the estimate of the investment's recoverable amount after considering the perceived capacity of the defendant to meet the claim and any other pertinent factors. Such amount is not necessarily the amount being claimed, nor is it an estimate of the return to the Group if the investment is successful. It includes the amount to the funded client and to the Group. It does not include co-funder portion
		ii. a funding commission calculated as a multiple of the capital deployed; EPV is arrived at by taking the estimated potential income from the investment to the funding entity and grossing this up to an EPV using the Long–Term Conversion Rate at the time estimation. It does not include co-funder portion, or
		iii. a funding commission calculated on a combination of the above bases or on an alternative basis, arriving at the EPV may utilise one of the above methodologies, or a hybrid construct, or an alternative methodology depending upon the components of the funding commission.
		OBE Group's EPV has been estimated on a conceptually consistent basis noting that, enforcement case investments may have a multi-layered approach from a timing and value perspective.
		Regardless of how calculated, an EPV is an estimate and is subject to change over time for a number of reasons, including, but not limited to, changes in circumstances and knowledge relating to an investment or the defendant(s) perceived capacity to meet the claim, partial recovery and, where applicable, ability to enforce or recover.
		Possible EPVs are reviewed and updated where necessary.
₹IF	FRS	International Financial Reporting Standards.
$\int \Gamma$	TIP	Long-Term Incentive Plan.
N	ICI	Non-controlling interest. This represents the interests of external Fund investors in funds that are consolidated within the Group, in accordance with each of the respective Funds' return waterfall.
))0	BE Group	Omni Bridgeway Holdings BV and subsidiary; it includes Fund 6 and Fund 7.
0)BL	Omni Bridgeway Limited (ABN 45 067 298 088).
S	TIP	Short Term-Incentive Program.

Non-IFRS financial information included in this Report has been prepared in accordance with ASIC Regulatory Guidance 230 - Disclosing Non-IFRS financial information, issued December 2011. This information has not been audited or reviewed.

Disclaimer

TSR

Total shareholder return.

None of the content in the Omni Bridgeway Limited ("OBL") Interim Financial Report is an offer to sell, or a solicitation of an offer to buy, any securities of OBL or any other company affiliated with OBL. In addition, nothing herein should be construed as an offer to buy or sell, nor a solicitation of an offer to buy or sell, any security or other financial instrument, or to invest assets in any account managed or advised by OBL or its affiliates. This Interim Financial Report is for the use of OBL's public shareholders and is not an offering of any OBL private fund.



Americas

Chicago

+1 872 260 2057

500 West Madison Street Suite 1000 Chicago IL 60661 United States

Dallas

+1 212 488 5331 United States

Houston

+1 713 965 7919

LyondellBasell Tower 1221 McKinney Street Suite 2860 Houston TX 77010 United States

Los Angeles

+1 213 550 2687 555 W. Fifth Street Suite 3310 Los Angeles CA 90013 United States

Miami

+1 786 891 2228 2 South Biscayne Blvd. Suite 3200 Miami FL 33131 United States

Minneapolis

+1 612 488 9211

60 South 6th Street Suite 2800 Minneapolis MN 55402 United States

New York

+1 212 488 5331

437 Madison Avenue 36th Floor New York NY 10022 United States

San Francisco

+1 415 231 0363

50 California Street Suite 2930 San Francisco CA 94111 United States

Washington, D.C.

+1 212 488 5331

2101 L Street, N.W. Suite 925 Washington, D.C. 20037 United States

Montreal

+1 514 257 6971

60 rue St-Jacques Bureau 401 Montréal QC H2Y 1L5 Canada

Toronto

+1 416 583 5720

250 The Esplanade Suite 127 Toronto ON M5A 1J2 Canada

Montevideo

+1 514 257 6971 Uruguay

Asia-Pacific

Melbourne

+61 3 9913 3301

Level 3 Bourke Place 600 Bourke Street Melbourne VIC 3000 Australia

Perth

+61 8 9225 2300

Level 10 66 St Georges Terrace Perth WA 6000 Australia

Sydney

+61 2 8223 3567

Level 7 35 Clarence Street Sydney NSW 2000 Australia

Hong Kong

+852 3978 2629 11/F Tower 2 Admiralty Centre 18 Harcourt Rd, Admiralty Hong Kong

Singapore

+65 6813 2647

Level 13-03 6 Battery Road Singapore 049909

Auckland

+64 21 990 620

Level 2 1 Albert Street Auckland 1010 New Zealand

Europe, Middle East & Africa

Amsterdam

+31 70 338 4343

Schiphol Boulevard 121 1118 BG Schiphol Amsterdam The Netherlands

Cologne

+49 221 801155-0

Gereonstr. 43-65 50670 Cologne Germany

Geneva

+41 22 818 6300

Rue de la Rôtisserie 4 1204 Geneva Switzerland

London

+44 203 968 6061

Link House 78 Cowcross Street London EC1M 6EJ United Kingdom

Madrid

+31 70 338 4343

Spain

Milan

+39 339 448 3907

Via Fatebenefratelli, 5 20121 Milano MI Italy

Paris

+33 6 5159 4359

31 rue du Colisée 75008 Paris France

Dubai

+971 4 514 4608

Unit 1905, Level 19 Index Tower Dubai International Financial Centre 507152 Dubai United Arab Emirates